Endovascular Treatment in Ischemic Stroke Follow-up Evaluation

Study Overview
=================
Brief Summary
-----------------
Study like register with biomarkers samples for patient experiencing acute ischemic stroke, to assess clinical outcomes and different factors that may affect the clinical outcomes.

Official Title
-----------------
Evaluation of Clinical and Imaging Criteria, and Plasma Biomarkers of Patients Receiving an Endovascular Treatment for an Acute Ischemic Stroke

Conditions
-----------------
Stroke, Acute

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 and older (i.e., candidates must have had their 18th birthday) Neuroimaging demonstrates acute ischemic stroke with large vessel proximal with the use of neuro-thrombectomy devices intended to restore blood flow No upper or lower limits of the neurological severity at baseline (NIHSS). With or without intravenous thrombolysis Oral informed consent (patient and/or trustworthy person) Non-inclusion Criteria: Pregnant or breast-feeding women Patient benefiting from a legal protection Non-membership of a national insurance scheme

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Arterial Ischemic Stroke (AIS)<br>All patients (prospective and retrospective) included will have to present an Arterial Ischemic Stroke (AIS) from a large cerebral vessel occlusion. The participation in the study will consist in: Plasmatic collection at the time of AIS, for study of plasma biomarkers Additional standardized blinded clinical evaluation at three months after the thrombectomy realized during a phone call, particularly via an assessment of the modified Rankin score. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical outcome | modified Rankin score (mRS), score 0 to 6 with 0 = no symptoms and 6 = death. | Day 90 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy on reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 2b/3) | Rate of complete or near complete reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 2b/3) | Day 1 | 
| Efficacy on revascularization (>= mTICI 2b) | Time to achieve TICI 2b or better revascularization | Day 1 | 
| Efficacy on clinical outcome (mRS=0-1) | Rate of excellent functional outcome defined as a modified Rankin score (mRS) 0-1 | Day 90 | 
| Efficacy on functional independence (mRS 0-2) | Rate of functional independence defined as a modified Rankin score 0-2 | Day 90 | 
| Hemorrhage evaluated by imagery | Rate of symptomatic and asymptomatic intracerebral hemorrhage at MRI or CT scan | Day 0 | 
| Hematoma rate | Rate of parenchymal hematoma 2 | Day 1 | 
| Mortality rate | Rate of all-cause mortality | Day 90 | 
| Complication rate | Rate of periprocedural complications | Day 0 | 
| ASPECT (Alberta Stroke Program Early CT score) | Measure by Axial imaging, 10-point quantitative topographic CT scan score | Day O | 
| Parametric imaging | Diffusion, volume clinical-diffusion mismatch | Day 0 | 
| Imaging data | Angiographic imaging | Day 1 | 
| Blood sampling for research purpose | Search of biomarkers of stroke etiology and recovery | Day 0 |